Insider trade

Officer sold ~$704K of CORT shares in the open market

Traded Jan 6, 2026 · Filed Jan 9, 2026

Why it stands out

Corcept Therapeutics's Chief Development Officer sold $704K of Corcept Therapeutics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$703,656

Shares × reported transaction price

Timing vs results

63 days after results of Nov 4, 2025, 49 days before results of Feb 24, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−5.5%	−2.5%	−3.0%
30 days	+9.3%	−0.5%	+9.8%
90 days	+15.9%	−1.3%	+17.2%
180 days	+129.9%	+7.8%	+122.2%

Past results only. Not a forecast.

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $34.96 to $35.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

8mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance8mo ago

8mo ago

Derivative exercise or conversion — not an open-market buy.